ARTICLEhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_4/article-pS-1.xmlNCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/Suppl_4/article-pS-1.pdf2026-04-18NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectiveshttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p953.xmlHave We Been Down This Road Before?2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p953.pdf2026-04-18Have We Been Down This Road Before?https://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-pxvii.xmlNCCN News2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-pxvii.pdf2026-04-18NCCN Newshttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-pxxxiii.xmlOncology Research Program2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-pxxxiii.pdf2026-04-18Oncology Research Programhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p960.xmlKidney Cancer2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p960.pdf2026-04-18Kidney Cancerhttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p955.xmlWhat Level of Evidence: The Elusive Balance in Drug Development2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p955.pdf2026-04-18What Level of Evidence: The Elusive Balance in Drug Developmenthttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p1011.xmlRole of Immunotherapy for Renal Cell Cancer in 20112026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p1011.pdf2026-04-18Role of Immunotherapy for Renal Cell Cancer in 2011https://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p985.xmlRole of Surgery for Locally Advanced and Metastatic Renal Cell Carcinoma2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p985.pdf2026-04-18Role of Surgery for Locally Advanced and Metastatic Renal Cell Carcinomahttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p997.xmlSelecting Targeted Therapies for Patients With Renal Cell Carcinoma2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p997.pdf2026-04-18Selecting Targeted Therapies for Patients With Renal Cell Carcinomahttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p1020.xmlHodgkin Lymphoma2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p1020.pdf2026-04-18Hodgkin Lymphomahttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p1060.xmlThe Role of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p1060.pdf2026-04-18The Role of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomahttps://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p1073.xmlEvolution of Radiation Therapy Within the German Hodgkin Study Group Trials2026-04-18https://harbor.dev.pubfactory.com/view/journals/jnccn/9/9/article-p1073.pdf2026-04-18Evolution of Radiation Therapy Within the German Hodgkin Study Group Trials